SPONSOR
Peter MacCallum Cancer Centre, Australia
Total Trials
5
Recruiting
5
Phases
Phase 1, Phase 2
Conditions studied: Invasive Fungal InfectionsExtramedullary MyelomaRelapsed/Refractory Large B-cell LymphomaMelanoma (Skin Cancer)Inherited BMF SyndromeInherited Platelet DisorderHematologic Diseases
Peter MacCallum Cancer Centre, Australia is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Invasive Fungal Infections, Extramedullary Myeloma, Relapsed/Refractory Large B-cell Lymphoma, Melanoma (Skin Cancer).
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Peter MacCallum Cancer Centre, Australia
How many clinical trials has Peter MacCallum Cancer Centre, Australia sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Peter MacCallum Cancer Centre, Australia, of which 5 are actively recruiting participants. These trials cover conditions including Invasive Fungal Infections, Extramedullary Myeloma, Relapsed/Refractory Large B-cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Peter MacCallum Cancer Centre, Australia research focus on?
Peter MacCallum Cancer Centre, Australia clinical trials span Invasive Fungal Infections, Extramedullary Myeloma, Relapsed/Refractory Large B-cell Lymphoma, Melanoma (Skin Cancer), Inherited BMF Syndrome, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Peter MacCallum Cancer Centre, Australia clinical trial?
To participate in a Peter MacCallum Cancer Centre, Australia trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peter MacCallum Cancer Centre, Australia trials with current recruitment status updated daily.
Clinical Trials by Peter MacCallum Cancer Centre, Australia
NCT06105411
Recruiting
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
Invasive Fungal Infections
NCT05666700 Phase 1
Recruiting
CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study
Extramedullary Myeloma
NCT06414148 Phase 2
Recruiting
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Relapsed/Refractory Large B-cell Lymphoma
NCT07138222
Recruiting
IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
Melanoma (Skin Cancer)
NCT05196789
Recruiting
Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)
Inherited BMF Syndrome
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology